AXL and neoplasm: We present evidence that gilteritinib inhibits cell survival, triggers apoptosis and cell cycle arrest, and reduces cell motility, further suggesting that gilteritinib has therapeutic potential for tumor activity in AXL-positive solid tumor cells.